145 related articles for article (PubMed ID: 7515169)
21. [Interferon-alpha in therapy of malignant hemoblastoses].
Schuler M; Aulitzky WE; Schneller F; Peschel C; Huber C
Internist (Berl); 1995 Dec; 36(12):1133-8. PubMed ID: 8567218
[No Abstract] [Full Text] [Related]
22. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
[TBL] [Abstract][Full Text] [Related]
23. Biologic therapy of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Gutterman J
Oncology (Williston Park); 1987 Sep; 1(7):35-40, 48-9, 52. PubMed ID: 3152810
[TBL] [Abstract][Full Text] [Related]
24. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
[TBL] [Abstract][Full Text] [Related]
25. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
[TBL] [Abstract][Full Text] [Related]
26. Single-tube quantitative RT-PCR for monitoring of the response to IFN treatment in CML patients.
Moravcová J; Muchová S; Kalbácová R; Haskovec C
Leukemia; 1998 Aug; 12(8):1326-7. PubMed ID: 9697892
[No Abstract] [Full Text] [Related]
27. Multiple myeloma preceding the development of chronic myelogenous leukemia.
Nitta M; Tsuboi K; Yamashita S; Kato M; Hayami Y; Harada S; Komatsu H; Iida S; Banno S; Wakita A; Ueda R
Int J Hematol; 1999 Apr; 69(3):170-3. PubMed ID: 10222655
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
29. Cytokine therapy for hematological malignancies.
Ezaki K
Int J Hematol; 1996 Dec; 65(1):17-29. PubMed ID: 8990622
[TBL] [Abstract][Full Text] [Related]
30. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
Skotnicki AB; Wolska-Smoleń T
Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy.
Thiele J; Zirbes TK; Lorenzen J; Kvasnicka HM; Dresbach S; Manich B; Leder LD; Niederle N; Diehl V; Fischer R
J Pathol; 1997 Mar; 181(3):316-22. PubMed ID: 9155719
[TBL] [Abstract][Full Text] [Related]
32. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
[TBL] [Abstract][Full Text] [Related]
33. Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines.
Andrews DF; Singer JW; Collins SJ
Cancer Res; 1987 Dec; 47(24 Pt 1):6629-32. PubMed ID: 3479248
[TBL] [Abstract][Full Text] [Related]
34. Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase.
Meloni G; De Fabritiis P; Alimena G; Malagnino F; Montefusco E; Sandrelli A; Pinto R; Vignetti M; Lo Coco F; Mandelli F
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():92-4. PubMed ID: 2576389
[TBL] [Abstract][Full Text] [Related]
35. [Different sensitivity of two chronic myeloid leukemia cell lines to interferon-alpha].
Li XM; Chen HC; Liu XF; Wu YH; Cao YF
Ai Zheng; 2003 Oct; 22(10):1047-52. PubMed ID: 14558948
[TBL] [Abstract][Full Text] [Related]
36. [Value of interferon-alpha in treatment of chronic myeloid leukemia].
Thaler J
Acta Med Austriaca; 1993; 20(3):65-9. PubMed ID: 8368048
[TBL] [Abstract][Full Text] [Related]
37. Clinical and histological features retain their prognostic impact under interferon therapy of CML: a pilot study.
Thiele J; Kvasnicka HM; Niederle N; Kloke O; Schmidt M; Lienhard H; Zirbes T; Meuter RB; Leder LD; Fischer R
Am J Hematol; 1995 Sep; 50(1):30-9. PubMed ID: 7545352
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia.
Singhal N; Bapsy PP; Babu KG; George J
J Assoc Physicians India; 2004 May; 52():410-6. PubMed ID: 15656033
[TBL] [Abstract][Full Text] [Related]
39. [Recent progress in therapy for chronic myelogenous leukemia].
Urabe A
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
